CYP2C9*1B Promoter Polymorphisms, in Linkage with CYP2C19*2, Affect Phenytoin Autoinduction of Clearance and Maintenance Dose

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2010-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/jpet.109.161026PMID 19855097PMCID PMC2812115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes

  2009cited by this paper
• Peroxidase-Mediated Bioactivation of Hydroxylated Metabolites of Carbamazepine and Phenytoin

  2008influential reference
• Novel CYP2C9 Promoter Variants and Assessment of Their Impact on Gene Expression

  2008influential reference
• Changes in Gene Expression Induced by Carbamazepine and Phenytoin: Testing the Danger Hypothesis

  2008influential reference
• Use of antiepileptic medications in nursing homes.

  2007cited by this paper
• Epilepsy in the elderly: scope of the problem.

  2007cited by this paper
• Activation of human CYP2C9 promoter and regulation by CAR and PXR in mouse liver.

  2006cited by this paper
• Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients.

  2006influential reference
• HIGH VOLUME BIOASSAYS TO ASSESS CYP3A4-MEDIATED DRUG INTERACTIONS: INDUCTION AND INHIBITION IN A SINGLE CELL LINE

  2005cited by this paper
• Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

  2005cited by this paper
• CYP2C9 Haplotype Structure in European American Warfarin Patients and Association with Clinical Outcomes

  2005cited by this paper
• The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.

  2004cited by this paper
• Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor

  2004cited by this paper
• Novel CYP2C9 genetic variants in asian subjects and their influence on maintenance warfarin dose

  2004cited by this paper
• Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man

  2004cited by this paper
• Human Constitutive Androstane Receptor Mediates Induction of CYP2B6 Gene Expression by Phenytoin*

  2004cited by this paper
• Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism

  2002cited by this paper
• CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.

  2002cited by this paper
• Intergenic transcripts containing a novel human cytochrome P450 2C exon 1 spliced to sequences from the CYP2C9 gene.

  2001cited by this paper
• Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine

  2001cited by this paper
• Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation.

  2000cited by this paper
• Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4.

  2000cited by this paper
• A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin.

  1999cited by this paper
• Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.

  1999cited by this paper
• Phenytoin auto-induction.

  1998cited by this paper
• Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.

  1997cited by this paper
• Allelic and functional variability of cytochrome P4502C9.

  1997cited by this paper
• The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

  1996cited by this paper
• Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite.

  1996cited by this paper
• Genetic analysis of the human cytochrome P450 CYP2C9 locus.

  1996cited by this paper
• The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

  1994cited by this paper
• Phenytoin auto-induction? Case reports.

  1989cited by this paper
• Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin.

  1985cited by this paper
• Phenytoin cumulation profiles.

  1983cited by this paper
• Phenytoin cumulation profiles.

  1983cited by this paper

• Nrf2 Ameliorates Atrial Fibrosis During Antithrombotic Therapy for Atrial Fibrillation by Modulating CYP2C9 Activity

  2024cites this paper
• An analysis of the Michaelis-Menten pharmacokinetics of phenytoin in epileptic Indonesian adults

  2023cites this paper
• Pharmacogenetic variants of CYP2C9 and CYP2C19 associated with adverse reactions induced by antiepileptic drugs used in Peru

  2023cites this paper
• Pharmacogenetic variants of CYP2C9 and CYP2C19 associated with adverse reactions induced by antiepileptic drugs used in Peru

  2023cites this paper
• Pharmacokinetic Modeling of Warfarin ІI – Model-Based Analysis of Warfarin Metabolites after Warfarin Administered Either Alone or Together with Fluconazole or Rifampin

  2022influential citation
• Pharmacokinetic Modeling of Warfarin І – Model-Based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals CYP2C9 Genotype-Dependent Drug-Drug Interactions of S-Warfarin

  2022influential citation
• A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various CYP2C9 Genotypes under Different Cotreatments

  2022cites this paper
• Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury

  2022cites this paper
• Concentration-Dependent Nonlinear Pharmacokinetics

  2021cites this paper
• HLA‐B*51:01 and CYP2C9*3 Are Risk Factors for Phenytoin‐Induced Eruption in the Japanese Population: Analysis of Data From the Biobank Japan Project

  2020cites this paper
• Estudio de genes candidatos sobre la efectividad y seguridad de la medicación anticonvulsiva en un grupo de pacientes colombianos afectados de epilepsia

  2020influential citation
• Association of SCN1A, SCN2A, and UGT2B7 Polymorphisms with Responsiveness to Valproic Acid in the Treatment of Epilepsy

  2020cites this paper
• Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel

  2019cites this paper
• Role of cytochrome P450-mediated metabolism and involvement of reactive metabolite formations on antiepileptic drug-induced liver injuries.

  2018cites this paper
• Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†

  2017cites this paper
• Regulation of hepatic energy metabolism by the nuclear receptor PXR.

  2016cites this paper
• Clinical Genomic Biomarker Assay Development: Technologies and Issues

  2016cites this paper
• Opportunities and challenges in using human hepatocytes in cytochromes P450 induction assays

  2016cites this paper
• Comparative Analysis of the Relationship Between Trichloroethylene Metabolism and Tissue-Specific Toxicity Among Inbred Mouse Strains: Liver Effects

  2015cites this paper
• Possible drug–drug interaction in dogs and cats resulted from alteration in drug metabolism: A mini review

  2015cites this paper
• Role of cytochrome P450-mediated metabolism and identification of novel thiol-conjugated metabolites in mice with phenytoin-induced liver injury.

  2015cites this paper
• Individualized Phenytoin Therapy for Japanese Pediatric Patients With Epilepsy Based on CYP2C9 and CYP2C19 Genotypes

  2015cites this paper
• Biotransformation in vitro: An essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data.

  2015cites this paper
• CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects

  2015cites this paper
• The Safety of Diclectin® in Breastfeeding

  2015cites this paper
• Antiepileptic drugs: Energy-consuming processes governing drug disposition.

  2014cites this paper
• Pregnane X receptor and drug-induced liver injury

  2014influential citation
• Effects of inter-strain differences in the metabolism of trichloroethylene on liver and kidney toxicity

  2014cites this paper
• CYP2C9 Polymorphism is not a Major Determinant of Bosentan Exposure in Healthy Volunteers

  2014cites this paper
• Pregnane X receptor (PXR) – a contributor to the diabetes epidemic?

  2014cites this paper
• Genetic Biomarkers in Epilepsy

  2014cites this paper
• Genetic studies of the common epilepsies: genome-wide association studies in the partial epilepsies

  2014cites this paper
• Role of cytochrome P 450-mediated metabolism and identi fi cation of novel thiol-conjugated metabolites in mice with phenytoin-induced liver injury

  2014cites this paper
• Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs

  2014cites this paper
• Chronic administration of phenytoin induces efflux transporter overexpression in rats

  2014cites this paper
• Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches.

  2013cites this paper
• Association of CYP2C9*2 With Bosentan‐Induced Liver Injury

  2013cites this paper
• Verapamil effect on phenytoin pharmacokinetics in rats.

  2013cites this paper
• A novel mouse model for phenytoin-induced liver injury: involvement of immune-related factors and P450-mediated metabolism.

  2013cites this paper
• Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects.

  2012cites this paper
• PharmGKB summary: phenytoin pathway

  2012influential citation
• The cytochrome P-450 2C9/2C19 but not the ABCB1 genetic polymorphism may be associated with the liver cytochrome 3A4 induction by phenytoin.

  2012cites this paper
• Clinical Pharmacology in Drug Labeling. The Impact of Drug Metabolism and Clinical Pharmacology on Recommended Dose of Drugs

  2012cites this paper
• A Practitioner’s Guide to Prescribing Phenytoin for Adults with Intellectual Disabilities

  2012cites this paper
• PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19

  2012cites this paper
• Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2.

  2012cites this paper
• A Case for Pharmacogenomics in Management of Cardiac Arrhythmias

  2012cites this paper
• CYP2C9 Promoter Variable Number Tandem Repeat Polymorphism Regulates mRNA Expression in Human Livers

  2012influential citation
• PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8

  2012cites this paper
• Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.

  2012cites this paper
• Pharmacogenomics and epilepsy: the road ahead.

  2011cites this paper
• Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics.

  2011cites this paper
• Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy

  2010influential citation
• Gene polymorphisms and their role in epilepsy treatment and prognosis

  2010cites this paper
• Newer Antiepileptic Drugs : Pharmacokinetics , Dosage , Major Side Effects , Drug Interactions

  year unknowncites this paper
• One Size Does Not Fit All : Personalized Treatment of Patients with Epilepsy

  year unknowncites this paper